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On the following pages you will find four documents: 
 
1)  A Patient Handout on the several “dangerous” drugs that have been in the news since the 
FDA official told Congress about them.  This Patient Handout covers Celebrex, Crestor, and 
several others. 
2)  A Patient Handout on JUST the COX-2 inhibitors and naproxen (Aleve, Naprosyn) for you to 
use if patients are asking about only these.   
3)  An FDA Talk Paper on use of COX-2 inhibitors and non-selective NSAIDs. 
4)  Professional Information for you covering all of these drugs. 
 
You may use your choice of either (or both) of the Patient Handouts to suit your needs.  Active 
subscribers have our permission to reproduce copies of the Patient Handouts for you to hand to 
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There have been a lot of recent news reports about some prescription drugs that may be 
dangerous.  These new reports started when Congress was holding a hearing about the painkiller, 
Vioxx, that was taken off the market.   
During a Congressional hearing an FDA staff member raised concerns about the safety of 
some other drugs.  He named several drugs: Accutane (isotretinoin), Arava (leflunomide), Bextra 
(valdecoxib), Crestor (rosuvastatin), Lotronex (alosetron), Meridia (sibutramine), and Serevent 
(salmeterol).   
Since the Congressional hearing there have been new reports about two drugs related to 
Vioxx.  The two painkiller drugs are Celebrex (celecoxib) and Bextra (valdecoxib).  Recently, 
Bextra was also withdrawn because of the reported problems. 
It is important to remember that millions of patients have taken all of these drugs, and the 




Many people take Accutane for severe acne.  It is a very effective medicine.  It’s well-known 
that Accutane can cause birth defects.  The problem is that pregnancies continue to occur in 
women taking Accutane despite strict registration programs and mandatory pregnancy blood 
tests.  Part of the problem is that some people get Accutane from a friend or from another 
country.   
Women shouldn’t take Accutane unless they can take strict precautions to avoid getting 
pregnant.  Women who are sexually active should always use two different forms of effective 
birth control.  They shouldn’t allow themselves to become pregnant for at least a month after 
stopping Accutane. 
Accutane can also make some patients feel depressed, irritable, or lead to suicidal thoughts.  
There have been suicides in patients taking Accutane.  Be certain to tell your physician and/or 
pharmacist right away if you have feelings of depression or self-harm while taking Accutane.   
 
Arava (leflunomide) 
Arava is an effective drug for treating severe rheumatoid arthritis.  Over the years there have 
been reports of serious lung or liver problems, but these are rare.  Patients on Arava should get 
frequent liver function tests to detect any liver problems that might occur.  Patients should also 
report any symptoms of liver problems such as unusual nausea, abdominal pain, fatigue, dark 
urine, pale stools, or yellow-looking eyes or skin.  If a person has any sign of infection that lasts 
more than a few days, the patient should see a doctor.  The signs of infection to watch for are a 
fever of or above 100.5 degrees, chills, severe sore throat, ear or nose pain, cough, or colored 
sputum. These might indicate a lung problem. 
 
Patient Handout 
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Bextra (valdecoxib) and Celebrex (celecoxib) 
Bextra and Celebrex (celecoxib) are used mainly for arthritis pain, menstrual pain, or other 
pain.  Many experts are concerned that Bextra and Celebrex can lead to an increased chance of 
heart problems or stroke.  Bextra and Celebrex are similar to Vioxx which was just taken off the 
market due to these types of problems.  As of April 2005, Bextra is no longer available because 
of these problems as well as the severe rash it can cause.  For more information on Bextra’s 
withdrawal from the market go to: 
http://www.fda.gov/medwatch/SAFETY/2005/safety05.htm#Bextra. 
The chance of a problem in any one patient is very low, but since the problem seems to be 
related to cardiovascular disease, it makes sense to try to avoid Celebrex in patients who have 
heart problems.  
Patients who have heart trouble and are taking Celebrex should talk with their health 
professional.  
People who are not likely to benefit from Celebrex may be better off on a regular NSAID 
(such as Motrin or Advil or a store’s brand product) or acetaminophen (such as Tylenol or a 
store’s brand product).  Patients should discuss this with their pharmacist, NP, PA, or physician.   




Just recently, the FDA issued a patient advisory statement on naproxen (Aleve, Naprosyn) 
which can be bought over-the-counter.  Preliminary information from an Alzheimer’s disease 
study showed some evidence of increased risk of cardiovascular events in patients taking 
naproxen.  The FDA advises that patients should not exceed the recommended dose of 220 mg 
twice daily for longer than ten days unless a physician directs otherwise. 
 
Crestor (rosuvastatin) 
Crestor is one of the statins used to lower cholesterol.  The consumer group called Public 
Citizen says it should be taken off the market because of possible kidney and liver problems.  These 
problems are rare and the risk can be minimized by using lower doses and checking kidney and 
liver function.  Anyone taking Crestor or another statin should call their health care professional if 
they start to get muscle pain or weakness, unusual nausea, abdominal pain, fatigue, dark urine, pain 
when urinating, pale stools, or yellow-looking eyes or skin.  
 
Lotronex (alosetron) 
Lotronex is used for women with Irritable Bowel Syndrome (IBS) who have diarrhea 
frequently, and have failed to get better on other treatments. Reports have been in the news about 
serious complications.  About 1 woman out of 1,000 who takes Lotronex may get complications 
such as severe constipation.  It can also cause ischemic colitis, which is caused by low blood 
flow to parts of the gut. About 1 woman out of 350 women who takes Lotronex over a 6 month 
period may get this.  Lotronex should never be used in patients who often have constipation.  
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Meridia is modestly effective for weight loss, but it can increase blood pressure and heart rate.  
There are reports of stroke and heart attack in patients taking Meridia, but it’s not known if these 
are caused by the drug.  Some obese patients already have high blood pressure or heart disease.  
Patients taking Meridia should check their blood pressure and heart rate at least weekly and 
report any sustained increases to their physician.   
 
Serevent (salmeterol) 
Serevent is used to prevent airway constriction in patients with asthma.  It’s called a long-
acting bronchodilator.  It may lead to an increased risk of severe asthma worsening, especially 
when the medicine is not used appropriately.  Serevent shouldn’t be used for sudden breathing 
difficulties.  A short-acting bronchodilator such as albuterol should be used for sudden breathing 
problems.  Also, Serevent should always be used with a drug that controls inflammation, such as 
an inhaled steroid to control asthma and reduce the risk of flare-ups.   
 
Remember 
Every medicine has side effects.  Your pharmacist, NP, PA, and physician know the possible 
side effects of drugs and can carefully weigh the benefit of medicines against their risks.  Your 
health care professional will review possible side effects with you and give you information 
about how to reduce these risks.  Be sure to ask any questions you have when a drug is 
prescribed or dispensed and while you are taking it.  Always follow the medication instructions 
that your health care professional gives you.  Never share medications since this is a very 
dangerous practice.  Be sure to get your medicines from a trusted pharmacist.   
 
If you have any concerns, please feel free to discuss them with the health care professional 


















Information for Patients Taking Celebrex or Naproxen 
 
Celebrex (celecoxib) and naproxen (Aleve, Naprosyn) are used mainly for pain such as arthritis 
pain.  Many patients also use them for menstrual pain.  Many experts are now concerned that 
Celebrex and naproxen can lead to an increased chance of heart problems or stroke.  Celebrex is 
similar to Vioxx and Bextra which were taken off the market due to these types of problems.  
Naproxen is a regular painkiller like Motrin or Advil. 
 
The chance of a problem in any one patient is very low.  It is important to remember that many 
millions of people have used these medicines and many are still using them.  Researchers 
continuously conduct studies to learn more about the drugs.  Recently, researchers were studying 
to see if Celebrex was useful to prevent colon cancer.  During the course of the study researchers 
noticed that there was an increase in heart problems in the people who were taking Celebrex.  
These studies usually run for years and involve many patients.  In this case it requires statistical 
calculations to determine that there was an increase in heart problems in the patients taking 
Celebrex.  Just recently, the FDA issued a patient advisory statement on naproxen (Aleve, 
Naprosyn) which can be bought over-the-counter.  Preliminary information from an Alzheimer’s 
disease study showed some evidence of increased risk of cardiovascular events in patients taking 
naproxen.  Any individual patient who has taken Celebrex or naproxen should not become overly 
concerned.  
 
Since the problem seems to be related to cardiovascular disease, it makes sense to try to avoid 
Celebrex in patients who have heart problems. Patients who have heart trouble and are taking 
Celebrex or naproxen should talk with their health care professional to see if some other therapy 
might be better for them.  
 
Bextra, Celebrex, and Vioxx are called COX-2 inhibitor drugs.  These drugs are actually in the 
same family of drugs that are called nonsteroidal anti-inflammatory drugs (NSAIDs).  One of the 
problems with some nonsteroidal anti-inflammatory drugs (NSAIDs) is that they can sometimes 
lead to bleeding in the stomach.  It was thought that the COX-2 drugs such as Bextra, Celebrex, 
and Vioxx would not lead to as much bleeding in the stomach as the other nonsteroidal anti-
inflammatory drugs (NSAIDs).  So patients who had ulcers or other chance of bleeding in the 
stomach or intestinal track often got a drug like Bextra, Celebrex, or Vioxx instead of the regular 
nonsteroidal anti-inflammatory drugs (NSAIDs). Pharmaceutical firms encouraged physicians to 
use these COX-2 drugs for many people.  Many people might be better off on an NSAID (such as 
Motrin, Advil, or a store’s brand product), or acetaminophen (such as Tylenol or a store’s brand 
product).  The FDA advises that patients should not exceed the recommended dose or duration 
printed on any over-the-counter medicine bottle unless a physician directs otherwise.  Patients 
should discuss this with their pharmacist, nurse practitioner, physician assistant, and/or physician.   
 
There was a separate concern related to Bextra.  It could cause severe rash, which in some cases 
was life-threatening.  This reaction was unpredictable, and could happen after short or long 
periods of use.  In April 2005, the FDA asked Pfizer, the manufacturer of Bextra, to voluntarily 
withdraw Bextra from the market. 
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FDA Issues Public Health Advisory  
Recommending Limited Use of Cox-2 Inhibitors 
 
 
The following excerpts are reprinted from the 
December 23, 2004 FDA Talk Paper on 





Agency Requires Evaluation of Prevention 
Studies Involving Cox-2 Selective Agents 
The Food and Drug Administration (FDA) 
today issued a Public Health Advisory 
summarizing the agency's recent 
recommendations concerning the use of non-
steroidal anti-inflammatory drug products 
(NSAIDs), including those known as COX-2 
selective agents.  The public health advisory is an 
interim measure, pending further review of data 
that continue to be collected.  
In addition, FDA today announced that it is 
requiring evaluation of all prevention studies that 
involve the COX-2 selective agents Celebrex 
(celecoxib) and Bextra (valdecoxib) to ensure that 
adequate precautions are implemented in the 
studies and that local Institutional Review Boards 
re-evaluate them in light of the new evidence that 
these drugs may increase the risk of heart attack 
and stroke.  A prevention trial is one in which 
healthy people are given medicine to prevent a 
disease or condition (such as colon polyps or 
Alzheimer's disease). 
FDA is issuing an advisory because of recently 
released data from controlled clinical trials 
showing that the COX-2 selective agents (Vioxx, 
Celebrex, and Bextra) may be associated with an 
increased risk of serious cardiovascular events 
(heart attack and stroke), especially when they are 
used for long periods of time or in very high risk 
settings (immediately after heart surgery). 
Also, as FDA announced earlier this week, 
preliminary results from a long-term clinical trial 
(up to three years) suggest that long-term use of a 
non-selective NSAID, naproxen (sold as Aleve, 
Naprosyn, and other trade name and generic 
products), may be associated with an increased 
cardiovascular (CV) risk compared to placebo.  
Although the results of these studies are 
preliminary and conflict with other data from 
studies of the same drugs, FDA is making the 
following interim recommendations: 
Physicians prescribing Celebrex (celecoxib) or 
Bextra (valdecoxib) should consider this emerging 
information when weighing the benefits against 
risks for individual patients.  Patients who are at a 
high risk of gastrointestinal (GI) bleeding, have a 
history of intolerance to non-selective NSAIDs, or 
are not doing well on non-selective NSAIDs may 
be appropriate candidates for COX-2 selective 
agents.  
Individual patient risk for cardiovascular 
events and other risks commonly associated with 
NSAIDs should be taken into account for each 
prescribing situation.  
Consumers are advised that all over-the-
counter (OTC) pain medications, including 
NSAIDs, should be used in strict accordance with 
the label directions. If use of an (OTC) NSAID is 
needed for longer than ten days, a physician 
should be consulted.  
Non-selective NSAIDs are widely used in both 
over-the-counter (OTC) and prescription settings. 
As prescription drugs, many are approved for 
short-term use in the treatment of pain and 
primary dysmenorrhea (menstrual discomfort), 
and for longer-term use to treat the signs and 
symptoms of osteoarthritis and rheumatoid 
arthritis. FDA has previously posted extensive 
NSAID medication information at 
http://www.fda.gov/cder/drug/analgesics/default.h
tm.  
FDA is collecting and will be analyzing all 
available information from the most recent studies 
of Vioxx, Celebrex, Bextra, and naproxen, and 
(Detail-Document #210101) 
 
other data for COX-2 selective and nonselective 
NSAID products to determine whether additional 
regulatory action is needed.  An advisory 
committee meeting is planned for February 2005, 
which will provide for a full public discussion of 
these issues. 
FDA urges health care providers and patients 
to report adverse event information to FDA via 
the MedWatch program by phone (1-800-FDA-
1088), by fax (1-800-FDA-0178), or via the 
Internet at: 
http://www.fda.gov/medwatch/index.html. 





Users of this document are cautioned to use their own 
professional judgment and consult any other necessary 
or appropriate sources prior to making clinical 
judgments based on the content of this document.  Our 
editors have researched the information with input 
from experts, government agencies, and national 
organizations.  Information and Internet links in this 
article were current as of the date of publication. 
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“Dangerous Medications” - Preventing Serious Side Effects 
Lead author: Joseph A. Woelfel, Ph.D., FASCP, R.Ph., Assistant Editor 
 
Background 
Five drugs were recently cited as posing 
serious risks as identified by an FDA scientist.  
On November 18, 2004, Dr. David Graham 
testified before the US Senate Committee on 
Finance.  Dr. Graham is the Associate Director for 
Safety, Office of Drug Safety for the Food and 
Drug Administration.  In his presentation made at 
the hearing on FDA, Merck and Vioxx: Putting 
Patient Safety First, he identified five FDA-
approved “dangerous drugs.”  These include: the 
diet drug Meridia, the cholesterol drug Crestor, 
the acne medication Accutane, the anti-
inflammatory drug Bextra, and the asthma 
medicine Serevent.  In his written testimony on 
Vioxx, he included the arthritis drug Arava, and 
the irritable bowel agent, Lotronex.1   
In his testimony, he further stated “I would 
argue that the FDA as currently configured is 
incapable of protecting America against another 
Vioxx.  We are virtually defenseless.”  In response 
to his testimony, Finance Committee Chairman, 
Senator Chuck Grassley said “that’s exactly the 
opposite of what it should be.  The health and 
safety of the public must be the FDA’s first and 
only concern.”1   
The risks associated with these FDA-approved 
products that Dr. Graham identified are well 
known.  The larger concern is that there may be 
system problems in checks and balances for rapid 
drug approval vs safety assurance.   
 
Minimizing “Dangerous Drug” Effects 
Appropriate prescribing, dispensing, 
administration, and monitoring of medication use 
are essential for assurance of patient safety.   
Accutane (isotretinoin)-related birth defects 
and suicide or mental problems are well known.  
In 2002 an isotretinoin risk management program 
known as the System to Manage Accutane Related 
Teratogenicity (S.M.A.R.T.) was implemented.  
Currently the FDA is taking action to strengthen 
the risk minimization action plan (RiskMAP) for 
Accutane and the generic equivalents.  
Registration of prescribers, pharmacists, and 
patients will be required before dispensing of 
isotretinoin.  Pregnancy testing before and during 
isotretinoin is required.2   
The FDA Accutane Medication Guide is 
essential reading for all patients with each new or 
refill prescription.  Remind them to report any 
feelings of depression or suicide and for women to 
use two different forms of birth control.3 
Arava (leflunomide) for rheumatoid arthritis 
carries similar pregnancy warnings and 
contraindications.  Women wanting to become 
pregnant after receiving Arava must undergo a 
process using cholestyramine taken orally for 
eleven days to clear residual leflunomide from 
their system.  Interstitial lung disease is a serious 
but rare adverse reaction which was included in 
the November 2004 product label as a result of 
post-marketing surveillance data.  It can occur any 
time during treatment.  New onset or worsening 
pulmonary symptoms, such as cough and dyspnea, 
with or without associated fever, may be a sign of 
the often fatal problem and warrants follow-up or 
discontinuation.  Arava can cause hepatic 
problems.  An unacceptable risk of liver failure 
was mentioned by Dr. Graham.  Monitoring liver 
function should occur at baseline, at six and 12 
weeks after the start of therapy or dose elevation, 
then every six months.4  Patients should be 
reminded to report any signs of liver toxicity such 
as nausea, abdominal pain, dark urine, or 
jaundice.   
Bextra (valdecoxib) had a new black box 
warning, added in November 2004.  Serious skin 
rashes can occur anytime but usually occur within 
the first two weeks of therapy.  Advise patients to 
watch for rashes, lesions, or unusual swelling and 
discontinue Bextra at the first sign of these.  They 
(Detail-Document #210101:  Page 2 of 3) 
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should immediately call their health care 
professional when this occurs.  Patients who are 
recovering from coronary artery bypass graft 
(CABG) surgery should not receive Bextra.  In 
this group of patients Bextra is contraindicated 
due to cardiovascular thromboembolic adverse 
events.  A new bolded warning was added to the 
label.6  In recent correspondence to the editor 
published in the New England Journal of 
Medicine, it was suggested that Bextra’s use be 
limited until convincing evidence of 
cardiovascular safety is shown.7  On April 7, 2005 
the FDA requested that Pfizer withdraw Bextra 
from the market.15  For more information on 
Bextra’s withdrawal go to: 
http://www.fda.gov/medwatch/SAFETY/2005/saf
ety05.htm#Bextra. 
Crestor (rosuvastatin) like other statins can 
cause rhabdomyolysis or hepatotoxicity.  Patients 
should report any muscle pain or weakness as well 
as any signs of liver problems such as yellow skin 
or sclera.  The consumer advocacy group, Public 
Citizen, has admonished Crestor for causing 
kidney damage and rhabdomyolysis.  Kidney 
disease can increase the incidence of 
rhabdomyolysis and requires dosage adjustment.  
For patients with severe renal impairment (CL cr 
<30 mL/min/1.73m2) who are not on 
hemodialysis, a starting dose of 5 mg once daily is 
recommended and should not exceed 10 mg once 
daily.  Doses above 10 mg should not be 
administered to patients taking gemfibrozil 
(Lopid).  Initiation of therapy at a dose of 5 mg 
once daily should be considered for all Asian 
patients.  Lower starting doses are also 
recommended for the elderly and patients with 
untreated hypothyroidism.8 
Lotronex (alosetron) for irritable bowel 
syndrome lasting over six months in women was 
withdrawn from the market and then re-introduced 
in 2002 through a supplemental new drug 
application process.  The new label with 
prescribing restrictions, black box warning, and a 
Lotronex Risk Management Program reflected the 
serious adverse events with its use.  The incidence 
of serious complications of constipation in women 
was approximately 1 per 1,000 patients as shown 
in clinical trials.  The incidence of ischemic colitis 
was 3 per 1,000 women over a 6 month period.9  
Remind women receiving Lotronex to 
immediately report any constipation, abdominal 
discomfort, or intestinal bleeding. 
Meridia (sibutramine) for weight loss can 
increase blood pressure and also heart rate.  Obese 
patients may already present with underlying heart 
and vascular problems so caution in prescribing is 
essential.  Meridia is another product under 
scrutiny from Public Citizen because of these 
potentially dangerous side effects.10  Tell patients 
to check their blood pressure and heart rate 
regularly, at least weekly, and report any 
abnormal increases.  Emphasize healthy lifestyle 
changes. 
Serevent (salmeterol) received a black box 
warning label in 2003 concerning the rare but 
significant risk of asthma-related death shown in 
the Salmeterol Multi-center Asthma Research 
Trial (SMART).  The risk was greater in African 
American asthma patients.11  Life-threatening 
asthma exacerbation can be reduced by use of an 
inhaled corticosteroid as recommended in the 
National Asthma Education and Prevention 
Program (NAEPP) guidelines.12  Patients should 
also receive a short-acting bronchodilator for “as 
needed” bronchospasm use. 
Celebrex (celecoxib).  On December 17, 2004, 
Pfizer issued a news release that in the Adenoma 
Prevention with Celecoxib (APC) trial, patients 
taking 400 mg and 800 mg of Celebrex daily, had 
an approximately 2.5 fold increase in major fatal 
or non-fatal cardiovascular events compared with 
placebo.  As a result of this finding the APC colon 
cancer prevention trial was stopped.  Though 
higher-than-recommended doses were used in the 
trial, these findings further raise safety concerns.13  







On December 20, 2004, the FDA issued a 
patient advisory statement on naproxen (Aleve, 
Naprosyn).  Preliminary information from an 
Alzheimer’s disease study showed some evidence 
of increased risk of cardiovascular events in 
patients taking naproxen.  The FDA advises that 
patients should not exceed the recommended dose 
of 220 mg twice daily for longer than ten days 
unless a physician directs otherwise.14 
On April 7, 2005 the FDA announced that 
manufacturers of all marketed prescription 
NSAIDs, including Celebrex revise the labeling
(Detail-Document #210101:  Page 3 of 3) 
for their products to include a boxed warning and 
a Medication Guide.  The boxed warning 
highlights the potential for increased risk of 
cardiovascular events and the potentially life-
threatening gastrointestinal bleeding associated 
with their use.  A Medication Guide must 
accompany every prescription NSAID at the time 
of dispensing to better inform patients about these 
risks.  The FDA asked manufacturers of non-
prescription (OTC) NSAIDs to revise their 
labeling to include more specific information 
about the potential risks and provide information 
to assist consumers in the safe use of the drug.15
Active involvement by patients in managing 
their medication and health with health care 
professionals’ reassuring guidance will minimize 
the dangerous effects of these drugs. 
 
 
Users of this document are cautioned to use their own 
professional judgment and consult any other necessary 
or appropriate sources prior to making clinical 
judgments based on the content of this document.  Our 
editors have researched the information with input 
from experts, government agencies, and national 
organizations.  Information and Internet links in this 
article were current as of the date of publication. 
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